Idefirix

Imlifidase, the active ingredient in Idefirix, is a IgG‑degrading enzyme (recombinant) presented as an injectable solution for intravenous use. It is employed to rapidly lower donor‑specific IgG antibodies, facilitating desensitization of highly sensitized patients awaiting kidney transplantation. The drug is authorized in the European Union for use under prescription and is indicated for patients with high panel reactive antibody levels.

GNH USA supplies Idefirix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide, ensuring cold‑chain logistics and regulatory compliance.

Idefirix is used within the immunosuppressive pathway for kidney transplantation desensitization.

Highly sensitized kidney transplant candidates: enables rapid reduction of donor‑specific IgG antibodies to allow transplantation. Patients with elevated panel reactive antibody (PRA) levels: lowers circulating antibodies, improving compatibility for renal grafts.

Idefirix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions (fever, chills, flushing) - Headache - Nausea - Transient hypotension

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Cytokine release syndrome - Thromboembolic events (e.g., deep vein thrombosis)

Prior to initiating Idefirix therapy, several precautions should be observed.

Pregnancy: safety unknown; avoid unless potential benefit justifies risk. Infection risk: monitor for opportunistic infections due to immunoglobulin depletion. Hypersensitivity: assess for allergy to recombinant enzymes before infusion. Concomitant immunosuppression: adjust dosing of other agents and monitor immune status. Laboratory monitoring: check IgG and donor‑specific antibody levels before and after treatment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idefirix can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use of other IgG‑degrading enzymes: may cause excessive immunoglobulin loss. - Live vaccines: risk of uncontrolled infection; avoid administration during treatment.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., tacrolimus, mycophenolate): increased infection susceptibility; monitor patient. - Anticoagulants: potential for bleeding with infusion reactions; observe coagulation parameters. - Cytokine‑release‑inducing agents: additive risk of cytokine storm; watch for severe reactions. - B‑cell depleting monoclonal antibodies (e.g., rituximab): monitor immune reconstitution and infection risk.